Roberto Hegg

Av. Brigadeiro Luís Antônio, 683-Bela Vista
Sao Paulo, SP 01317000, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Journal: NPJ breast cancer

Published: December 15, 2025

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Journal: The New England journal of medicine

Published: October 22, 2025

Overall survival with abemaciclib in early breast cancer.

Overall survival with abemaciclib in early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

Journal: ESMO open

Published: July 08, 2025

Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial.

Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 12, 2025

Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.

Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.

Journal: Gynecologic oncology

Published: February 04, 2025

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Journal: Nature medicine

Published: June 24, 2024

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.

Journal: ESMO open

Published: November 06, 2023

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: November 02, 2022

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.

Journal: JAMA oncology

Published: June 02, 2022

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.

Journal: Breast cancer research and treatment

Published: April 25, 2022

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Journal: The New England journal of medicine

Published: March 23, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026